Delivering on Efficiency to Create Value. Stefan Oschmann Head of Pharmaceuticals
|
|
- Kathlyn Allison
- 5 years ago
- Views:
Transcription
1 Delivering on Efficiency to Create Value Stefan Oschmann Head of Pharmaceuticals London, September 20, 2012
2 Agenda 1. Overview Merck Group 2. Merck Serono strengths and revenue trends 3. Transforming Merck Serono 4. Conclusion and summary
3 Merck Group We have added scale while strengthening the attractiveness of assets in our portfolio 2002 Revenues 7.5 bn Transaction volume 2011 Revenues 10.3 bn Laboratory Distribution Divestments Millipore Merck Millipore Life Science Products Analytics & Reagents Electronic Chemicals Pigments Liquid Crystals CropBioscience 7 bn 16 bn Performance Materials Consumer Health Consumer Health Generics Acquisitions Serono Merck Serono Ethicals Theramex divested merged acquired 3
4 Agenda 1. Overview Merck Group 2. Merck Serono strengths and revenue trends 3. Transforming Merck Serono 4. Conclusion and summary
5 Merck Serono Merck Serono has many operational strengths Leadership positions and attractive franchises High exposure to biologic drugs Well-established products and brands in key areas and markets Global footprint - high percentage of revenues derived from emerging markets positively benefits overall growth profile ~2/3 of Merck Serono s drug portfolio are biologics 65% Biologics Neurodegenerative Diseases Oncology Fertility Endocrinology 35% High exposure to Biologics provides stability Small molecules Cardiometabolic Care Endocrinology 5
6 Merck Serono Lack of patent cliff provides resiliency to revenue streams Significantly less exposure to patent cliff compared to industry 25% 20% 15% 10% 5% 0% Sales lost to patent expiries as a % of 2010 group revenue Merck Big Pharma Key products protected for next three years - patent expiries: Rebif First formulation: EU 2015, US 2022 HSA-free* formulation: patent application pending; tentative expiry date 2024 (US, EU) Erbitux Data exclusivity: EU 2014, Japan 2016 (Post Marketing Surveillance) Gonal-f EU 2009, USA 2015 Strong brands such as Gonal-f provide additional protection Source: Sell-side research on Merck KGaA, June 23, 2011; corporate reports; Big Pharma incl. AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck & Co., Pfizer, Roche, Sanofi *human serum albumin - free 6
7 Merck Serono - Rebif Growth in the United States drives overall sales [ m] North America Price increase Price increase Price Volume Currency Global sales of 922 m in H (+6 % organic) Strong performance in US Market shares stabilizing Sales in Europe slightly declining Trend 0 Q Q Q Q [ m] 200 Europe Q2 performance Pricing pressures partly off-set by volume increase Growth 2012E: ~3 % organic sales growth Price Volume 50 0 Q Q Q Q
8 Merck Serono - Erbitux Emerging Markets strong, European sales weaker due to scale-down in Southern EU [ m] 250,0 200,0 150,0 100,0 50,0 Q2 y-o-y organic growth +28.5% +15.9% -1.0% Global sales of 439 m in H (+4 % organic) Patient shares above 50% in KRAS wt mcrc and SCCHN in key EU markets Growth 2012E: 1 4 % organic growth Filing for approval of Erbitux in head and neck cancer accepted for priority review in Japan 0,0 Q Q Q Q Q Q RoW Emerging Markets Europe 8
9 Merck Serono - Portfolio Over half of our portfolio is generating strong performance and will continue to grow 2011 Sales by business unit +3% organic growth +7% organic growth Key growth drivers ( m) Organic growth Gonal-f % Concor % 46% 54% Glucophage Endocrinology % +10 % Rebif & Erbitux All other Merck Serono products We have good assets that will continue to grow 9
10 Merck Serono H Emerging Markets is an increasing share of our sales and will drive attractive growth Sales by geography, organic growth rates Emerging Markets, mainly driven by Fertility and CMC/GM franchises Europe 43 %* 1,267 1,302-3 % North America benefitting especially from price increases in US Emerging Markets North America 29 % 21 % % +15 % More than off-setting ongoing price erosion in Europe, triggered by general austerity measures and tighter budget control RoW 7 % % H H Emerging Markets = Latin America + Asia (w/o Japan) ** ROW = Japan, Oceania, Australia, Africa 10 * Percentage of total sales
11 Merck Serono H Good underlying business momentum [ m] H H Δ Sales 2,964 2,740 8% EBITDA % One-time items EBITDA pre % % of sales 28.1% 28.0% Healthy organic sales growth (+5%) Reported EBITDA affected by restructuring costs EBITDA pre growth spurred by Tight control of marketing and selling spending Controlled spending in R&D Efficiency gains yet to come 11 EBITDA pre: EBITDA pre one-time items
12 Agenda 1. Overview Merck Group 2. Merck Serono strengths and revenue trends 3. Transforming Merck Serono 4. Conclusion and summary
13 Merck Serono Our ability to drive improved profitability is critical to ensure our future competitiveness bn Merck Serono revenues and profitability since ,0 5,754 5,920 5,5 5,0 4,5 4,480 5,014 5, Revenues: + 1,440m adj. OP: + 211m 1,0 1,125 1,197 1,002 1,279 1,336 0,5 0, Revenue Adj. Operating profit (underlying Core OR) Lack of effective operating leverage despite good top-line growth 13
14 Merck Serono We have a sense of urgency to deliver on efficiency Stable revenue and healthy margins Attractive double-digit growth by Emerging Markets Defense of Rebif franchise 2014 and beyond Competitive landscape in multiple sclerosis potentially intensifying Potential new Erbitux competition Further maturing of other product lines Continued growth from Erbitux Solid performance from Endocrinology and Fertility franchises 14 We have a two year window to deliver on efficiency
15 Merck Serono Breakdown of Merck Serono net cost savings through E Net savings Merck Serono by cost type 300m 200m 120 R&D P&L line: R&D 90 50m Commercial operations P&L line: SG&A 2012E 2013E 2014E 300 m of net cost savings by
16 Merck Serono SG&A Commercial operations will drive ~60% of Merck Serono s net cost savings 2014E Net savings in SG&A split into: Cost savings in commercial operations: Headquarter related costs ~20% Trim headquarter costs Eliminate double functions across the whole organization Regional country costs ~80% Downsize resources in administration and marketing along with the globalization of the organization Ensure appropriate levels of customer facing contacts 180 m of cost savings from Commercial Operations by
17 Merck Serono R&D We plan to deliver increased output with substantially fewer R&D personnel R&D Costs m 1 Distribution 2014E ~ 120m 808 Fixed costs (mainly headcount related) Variable costs (mainly project related) ~45% ~55% 2011A 2014E 1 Excludes local R&D, TechOps and other, totaling 297m in 2011, leading to a total annual R&D spend of 1.225m 2 Excluding local R&D, TechOps and other spend Headcount decrease drives fixed cost base reduction 17
18 Restructuring update We have made significant progress in implementing efficiency measures Efficiency Restructuring targets for Merck Serono and Merck Group Geneva headquarters closure Restructuring targets for Consumer Health Organic growth & pipeline Refreshed strategy for Rebif and other brands Improved franchise management (fertility, endocrinology, Emerging Markets) First major pipeline review done In-licensing of ONO-4641, TH-302 and Sym004 Biosimilar collaboration with Dr. Reddy s Cultural & organizational change Globalized functions in R&D and global organization Introduction of new incentive schemes Hiring of key personnel in level 2 and 3 18
19 Merck Serono - Pipeline We have begun the process of rebuilding our pipeline also through partnering activities Phase I Phase II Phase III TH-302 (cancer) Pimasertib (cancer) Sym 004 (SSCHN) Renewed in-licensing activity following the arrival of new Merck Serono management Pimasertib/PI3K (cancer) MEK Inhibitor (cancer) c-met KI (cancer) NHS-IL 12 (cancer) PI-2301 (MS) Fc-IFNbeta (MS) Sym 004 (mcrc) TH-302 (PC) Pimasertib (PC) Cilengitide (NSCLC) DI17E6 (mcrc) DI17E6 (mcrpc) recently in-licensed existing portfolio TH-302 (STS) Interested in predominantly phase I/II projects, also niche indications that are less attractive to big pharma Merck Serono offers strong expertise, particular in neurology and oncology Flexible approach to collaboration details IFNbeta XR (MS) ATX-MS-1467 (MS) Sprifermin (OA) ONO-4641 (MS) Atacicept (SLE) Sprifermin (CIR) Stimuvax (NSCLC) Cilengitide (GBM) Kuvan (PKU ped.) Recent deals with Ono Pharmaceuticals, Threshold Pharmaceuticals and Symphogen Pipeline has further improved, but significant work remains 19
20 Merck Serono - Biosimilars Alliance with Dr. Reddy s: Merck enters growing biosimilars market Rationale: Biosimilars market is attractive Focus on monoclonal antibodies in oncology + Experience in biosimilars Strength in generics Co-development agreement of Merck Serono and Dr. Reddy s Co-promotion rights in US and global marketing rights ex-us Dr. Reddy s responsible for Phase I, Merck for Phase III in manufacturing Creation of a powerful biosimilars platform Merck s biopharma expertise and emerging market set-up combined with a strong generics player experienced in biosimilars 20
21 Future R&D Oncology immunotherapy: A four pronged strategy Immuno Oncology Strategy Therapeutic Cancer vaccines Immunomodulation Immune environment Cancer stem cells Tumor Vaccines Stimuvax Nanovacc Blockade of Inhibitory Signals Anti-PD-L1 Inhibition of Cancer Inflammation FERi Anti-CD47 Anti-Muc1 Activation of APCs and Expansion of T cells NHS-IL12 Selectikine T regs and Metabolic Effects TGFβRi GCN2 Combo with CTX Treatment of Chronic Disease Curative Aim 21
22 Agenda 1. Overview Merck Group 2. Merck Serono strengths and revenue trends 3. Transforming Merck Serono 4. Conclusion and summary
23 Merck Serono mid-term financial targets Sales ( m) EBITDA pre ( m) +2% - 6% +15% - 21% 5,700-5,900 1,800-1, Assumptions: No new product launches Austerity measures will continue to put pressure on developed markets Emerging Markets will continue to fuel growth Royalty income to be expected to decrease to 180m 200m in 2014 * % of sales E E 28.2%* 31% 32%* Exploit Cost market savings potential will outside fundamentally Europe, especially improve in profitability Emerging Markets 23
24 Merck Group We now focus on efficiency Transformation process Efficiency De-complex organization Optimize cost structure Increase R&D productivity Organic growth Exploit leading market positions Execute selected bolt-on acquisitions Portfolio No portfolio divestments until 2014 No transformational deals before 2014 Cultural change Fill key positions with best managers Foster performance culture 24
25 Conclusion We are launching a major restructuring to improve our productivity We will deliver on our savings and profitability targets We are rebuilding our pipeline and we are off to a good start We will create value through efficiency and additional value could be 4 created from new product launches 25
Commerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationJP Morgan Healthcare Conference Stefan Oschmann Head of Pharma. San Francisco, January 9, 2012
JP Morgan Healthcare Conference Stefan Oschmann Head of Pharma San Francisco, January 9, 2012 Disclaimer Remarks All comparative figures relate to the corresponding last year s period. From 2007 the Generics
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationFINANCIAL PERSPECTIVES
FINANCIAL PERSPECTIVES M³ - Meet Merck Management Marcus Kuhnert, CFO Darmstadt December 10, 2015 Disclaimer Cautionary Note Regarding Forward-Looking Statements This communication may include forward-looking
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationIBP AT MERCK. Supply Chain Logistics summit - Barcelona. Didier Dayen Senior Director Global Advanced Planning. June 19 th, 2017
IBP AT MERCK Supply Chain Logistics summit - Barcelona Didier Dayen Senior Director Global Advanced Planning June 19 th, 2017 Content Who is Merck? IBP concept Benefits & Key Success Factors Conclusion
More informationBiopharmaceuticals Investor & Analyst Day
Biopharmaceuticals Investor & Analyst Day Roadmap to sustainable success Belén Garijo President & CEO Biopharmaceuticals Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative figures
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationMERCK KGAA, DARMSTADT, GERMANY
MERCK KGAA, DARMSTADT, GERMANY J.P. MORGAN 36TH ANNUAL HEALTHCARE CONFERENCE Belén Garijo, CEO Healthcare Udit Batra, CEO Life Science San Francisco January 8, 2018 Disclaimer Publication of Merck KGaA,
More informationLeading domestic players in India s pharmaceutical market in 2015
THE INDIAN PHARMACEUTICAL MARKET LEADING DOMESTIC COMPANIES 2015 Leading domestic players in India s pharmaceutical market in 2015 1 Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationTRUSTED GLOBAL LEADER
TRUSTED GLOBAL LEADER FULL YEAR RESULTS YEAR ENDED 30 JUNE 2017 OVERVIEW FY17 Highlights Gross profit* STRONG FULL YEAR PERFORMANCE FY15 53.7M ALL OPERATIONS CONTRIBUTING TO GOOD LEVELS OF ORGANIC GROWTH
More informationM³ - Meet the Management
DELIVER ON GROWTH M³ - Meet the Management Stefan Oschmann Vice Chairman of the Executive Board, Deputy CEO December 10, 2015 Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationISPE: Pharma Industry Outlook
ISPE: Pharma Industry Outlook ANDREW D. SKIBO Head of Global Biologics Operations & Global Engineering MedImmune/AstraZeneca Chairman, ISPE Board of Directors October 7, 2015 Linking Past ISPE Drivers
More informationMedical breakthroughs have always driven our business
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationGLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS
GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BIO021E May 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-288-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationRoche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010
Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationAstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationFor personal use only
ANNUAL GENERAL MEETING MINTER ELLISON LEVEL 23, 525 COLLINS ST, MELBOURNE VIC 3000 AT 11.00 AM ON 26 NOVEMBER, 2014 CEO S ADDRESS Thank you Roger. Good morning Ladies and Gentlemen. It is a pleasure to
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationFinancial targets breakdown Cost saving actions
Financial targets breakdown Cost saving actions Capital markets day 2017 N O V E M B E R 7-8, 2 0 1 7 N E W Y O R K Ericsson Internal 2017-10-06 Page 1 Carl Mellander CFO Ericsson Internal 2017-10-06 Page
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationJefferies Global Health Care Conference. June 1, 2015
Jefferies Global Health Care Conference June 1, 2015 Forward-Looking Statements This presentation may contain projections, estimates and other forwardlooking statements that involve a number of risks and
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationPHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationGlobal Pre-filled Syringes Market-Data, Analysis and Forecast to 2024
Global Pre-filled Syringes Market-Data, Analysis and Forecast to 2024 Pharmaceutical, healthcare, commercial and strategic developments in the Global Pre-Filled Syringes Market 2014-2024 www.gmrdata.com
More informationCompany Research. Dr Reddy s Laboratories- BUY with a Target of Rs 1,962. Investment overview- Business Overview-
Date-16-07-2012 Dr Reddy s Laboratories- BUY with a Target of Rs 1,962 Investment overview- Shareholders Information Global Generics grew by 68% to Rs 70,243mn in FY12 from Rs 53,340mn in Fy11. Therefore
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationRaymond James 34th Annual Institutional Investors Conference
Raymond James 34th Annual Institutional Investors Conference Thomas Werner, CFO March 5, 2013 Safe Harbor This material contains forward-looking statements within the meaning of the U.S. federal securities
More informationLife Sciences. Collaboration arrangement accounting. March 18, 2015
Life Sciences Collaboration arrangement accounting March 18, 2015 Disclaimer Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More informationSustainable Profitable Growth through Innovation. Pascal Soriot Chief Operating Officer Roche Pharmaceuticals
1 Sustainable Profitable Growth through Innovation Pascal Soriot Chief Operating Officer Roche Pharmaceuticals 2 Q1 2009: A good start into the year 3 Q1 2010: High growth for both divisions Well above
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationVISION & STRATEGY FIC LIC. Interview with the President
VISION & STRATEGY Interview with the President A conversation with Isao Teshirogi, President and CEO about the Shionogi Growth Strategy 2020 (SGS2020) VISION & STRATEGY SGS2020 Growth Strategies Under
More informationPatricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, (732)
Pharmaceutical Technology Patricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, pvanarnum@advanstar.com, (732) 346-3072 Biopharmaceutical Industry in 2012: Optimism on the Rise
More informationGlobal and China Biopharmaceutical Industry Report, 2010
Global and China Biopharmaceutical Industry Report, 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound
More informationMERCK BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE Belén Garijo CEO Healthcare. London, September 13, 2017
MERCK BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE 2017 Belén Garijo CEO London, September 13, 2017 Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators
More informationEVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE
, 09 MAY 2018 EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE 55% INCREASE IN GROUP REVENUES STRONG UNDERLYING OPERATIONAL PERFORMANCE WITH NEW BUSINESS MIX AFTER APTUIT ACQUISITION
More informationAGM PRESENTATION 8 November 2018
AGM PRESENTATION 8 November 2018 OVERVIEW Highlights STRONG FINANCIAL PERFORMANCE WITH MORE THAN 10% GROWTH IN ADJUSTED GROSS PROFIT*, EBITDA* & EPS* EXCELLENT PERFORMANCE BY COMMERCIAL MEDICINES GOOD
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationIntellectual Property and Academic- Industrial Collaboration
Intellectual Property and Academic- Industrial Collaboration J. Denry Sato, D.Phil Visiting Professor of Industry-Academia- Government Collaboration Hiroshima University Funding Problem for Educational
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Giovanni Caforio Chief Operating Officer January 13, 2015 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects
More informationPromotion and Development Collaborations Between Established Players
Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More information- PRESS RELEASE April 6 th, 2007 PRESS RELEASE April 6 th, PRESS RELEASE -
GENFIT S FINANCIAL RESULTS FOR 2006: PROFITABLE FOR THE 7 TH CONSECUTIVE YEAR DESPITE STRONGER INVESTMENT to the BENEFIT of the DRUG CANDIDATE PIPELINE - Profitable for the 7th consecutive year - Renewed
More informationResults Presentation Fiscal 2016 First Quarter
Results Presentation Fiscal 2016 First Quarter (January 1, 2016 March 31, 2016) Kyowa Hakko Kirin Co., Ltd. 2015 Kyowa Hakko Kirin Co., Ltd. Agenda FY 2016 Q1 Highlights Financial review Kazuyoshi Tachibana,
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More information37 th. Annual General Meeting. July 24, 2015 Biocon Research Centre. Chairperson s Speech. Kiran Mazumdar Shaw, Chairperson & Managing Director
37 th Annual General Meeting July 24, 2015 Biocon Research Centre Chairperson s Speech Kiran Mazumdar Shaw, Chairperson & Managing Director Welcome Biocon marks another successful year of providing affordable
More informationAUROBINDO S EUROPEAN OPERATIONS BINDING AGREEMENT TO ACQUIRE GENERIS IN PORTUGAL. January 2017
AUROBINDO S EUROPEAN OPERATIONS BINDING AGREEMENT TO ACQUIRE GENERIS IN PORTUGAL January 2017 Forward Looking Statements This presentation contains statements that constitute forward looking statements
More informationClinical Supply Packaging for Biological Products
Clinical Supply Packaging for Biological Products Part 2 of the Clinical Supply Knowledge Share Series: Understanding and Delivering your Global Clinical Supply Chain Almac Clinical Services Clinical Supply
More informationMoberg Pharma AB. Interim report, January June 2016 CREATING A FOOTPRINT IN UNDERSERVED NICHES
Moberg Pharma AB Interim report, January June 2016 CREATING A FOOTPRINT IN UNDERSERVED NICHES Conference call, August 9, 2016 at 3:00 p.m. (CET) Dial-in number: SE: +46 8 566 426 95, US: +1 646 502 51
More informationStrategic Overview of the Biotechnology Industry
Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationRecent Trends in Companion Diagnostic Test Development Partnerships
Recent Trends in Companion Diagnostic Test Development Partnerships Andrew S. Thompson, PhD, Director of Therapy and Analysis, GlobalData Medical, London Tyler Fletcher, Global Head, GlobalData Medical,
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationEli Lilly and Company
Eli Lilly and Company Acquisition of ImClone Systems, Inc. October 6 th, 2008 SEC Disclosure During this conference call, we anticipate making projections and forward-looking statements that are based
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited Company Presentation Rodman & Renshaw Annual Investment Conference September 9, 2014 Stefan Cross, President Mayne Pharma USA Mayne Pharma is a diverse global pharma company
More information[International] Source of Value-Creating Capability: Diversifying the Portfolio on a Global Basis
[International] Source of Value-Creating Capability: Diversifying the Portfolio on a Global Basis Diversifying the portfolio on a global basis Progress and future strategy Tim Andree Director and Executive
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationParameters of Development - Drug Delivery Enabled/Enhanced Products (DDEP ) A Review (Chapter 7)
CHAPTER 7 FDA DRUG APPROVALS, 2000-2010 Introduction This chapter reviews drug delivery enabled/enhanced product approvals by the FDA over the period 2000-2010. This is a simple analysis that provides
More informationDevelopment of differentiated immuno-oncology therapeutics by using multivalent Nanobodies
Nanobodies Innovative therapeutics Development of differentiated immuno-oncology therapeutics by using multivalent Nanobodies Immune Checkpoint Inhibitors Europe Sandra Li - 17 November 2016 Forward looking
More informationLUPIN LIMITED. J.P. Morgan Healthcare Conference January 8 th, Vinita Gupta, CEO
LUPIN LIMITED J.P. Morgan Healthcare Conference January 8 th, 2019 Vinita Gupta, CEO Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements.
More information35 th Annual J.P. Morgan Healthcare Conference. Gwan Sun Lee. President & CEO
35 th Annual J.P. Morgan Healthcare Conference Gwan Sun Lee President & CEO This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses
More informationStaying the Course. Life Sciences and Materials Sciences. Feike Sijbesma Chairman Managing Board. December 3, 2009 Merrill Lynch Conference, London
Life Sciences and Materials Sciences Staying the Course Feike Sijbesma Chairman Managing Board December 3, 2009 Merrill Lynch Conference, London 0 Agenda Current business conditions DSM is Staying the
More informationDr. Reddy s Laboratories Limited Investor Presentation June 2013 LIFE. RESEARCH. HOPE
Dr. Reddy s Laboratories Limited Investor Presentation June 2013 LIFE. RESEARCH. HOPE Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties
More informationMylan. Raymond James 40 th Annual Institutional Investors Conference March 05, 2019
Mylan Raymond James 40 th Annual Institutional Investors Conference March 05, 2019 Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationGlobal Pharmaceutical Industry Profile 2012
2012 1. Global Pharmaceuticals Market 1.1 Pharmaceutical Sector (Market) Performance The global pharmaceutical market has shown steady growth throughout the years. In particular, the market size of the
More informationAmgen Supply Chain Segmentation The Journey to October 23, 2014
Amgen Supply Chain Segmentation The Journey to 2022 October 23, 2014 Introduction Rayne Waller VP Global Supply Chain at Amgen Responsible for: Corporate and Regional Supply Chain Functions Contract Manufacturing
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationBranded Products Strategy. Helmut Kraft, CFO
Branded Products Strategy Helmut Kraft, CFO Changing the face of STADA Branded Products contribute 51% to adjusted operating profit 1) 46% 51% 51% 36% 37% 32% 26% 27% 28% 33% 36% 39% 2009 2010 2011 2012
More informationPartnering Activity Update. November 6, 2017
Partnering Activity Update November 6, 2017 Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner 2010 KYPROLIS / Carfilzomib Multiple Myeloma / Proteasome inhibitor
More informationCancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development
Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development Phil L Huillier Director Cancer Research Technology Ltd London, UK Who we are Cancer Research
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationBringing a successful partnership to the next level
Bringing a successful partnership to the next level Basle, 21 July 2008 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as
More informationSpeech Nancy McKinstry Annual General Meeting of Shareholders 2008 April 22, 2008 Okura Hotel Amsterdam
Speech Nancy McKinstry Annual General Meeting of Shareholders 2008 April 22, 2008 Okura Hotel Amsterdam Welcome and good morning. It is a pleasure to be here today to share our 2007 results and provide
More informationInvestor Presentation
Investor Presentation Michael Willome, Group CEO Baader Helvea Swiss Equities Conference Content Group overview & priorities Page 3 Segment performance, sales trend & outlook Page 10 Appendix: Leadership
More informationRoche Committed to innovation and profitable growth. Dr. Nina Mojas Dr. Luis Correia Investor Relations Officers. Zurich, March 2012
Roche Committed to innovation and profitable growth Dr. Nina Mojas Dr. Luis Correia Investor Relations Officers Zurich, March 2012 1 This presentation contains certain forward-looking statements. These
More informationQuarterly Results. Clariant Reports Strong Cash Flow Despite Continuing Weak Demand
www.clariant.com Clariant International Ltd Rothausstrasse 61 4132 Muttenz 1 Switzerland Second Quarter 2009, Clariant Reports Strong Cash Flow Despite Continuing Weak Demand Sales in Q2 down 21% in local
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation September 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.4% With a Global Footprint Revenue
More informationJefferies 2016 Healthcare Conference. June 8, 2016
Jefferies 2016 Healthcare Conference June 8, 2016 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
More informationGuide to Valuation of Pharmaceutical Licensing Deals Table of Contents
Guide to Valuation of Pharmaceutical Licensing Deals 2015 Table of Contents IMS HEALTH 210 Pentonville Road London N1 9JY United Kingdom Tel: +44 (0)20 3075 5876 For enquiries, please contact: Denis Mason
More informationScience For A Better Life. Morgan Stanley Consumer Health Symposium. Gary Balkema President, Consumer Care Bayer HealthCare
Science For A Better Life Morgan Stanley Consumer Health Symposium Gary Balkema President, Consumer Care Bayer HealthCare January 25 2008 Important Information This presentation may contain forward-looking
More informationMarch 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma. by Tim van Tongeren with Dennis van Rooij and Carlos Capella
March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma by Tim van Tongeren with Dennis van Rooij and Carlos Capella Executive Summary Each year, the pharmaceutical industry
More informationWe work with passion, using advanced technologies, to transform life science into new possibilities for our customers
We work with passion, using advanced technologies, to transform life science into new possibilities for our customers Business Update: First Quarter 2009 23 April 2009 Stefan Borgas Chief Executive Officer
More informationGap Inc. to Separate into Two Independent Companies to Maximize Long-Term Value Creation. February 28, 2019
Gap Inc. to Separate into Two Independent Companies to Maximize Long-Term Value Creation February 28, 2019 Forward Looking Statements This conference call and webcast contain forward-looking statements
More informationEvaluate Data Kit Pharma, Biotech and Medtech, May 2018
Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Contents Introduction 2 Sourcing Instructions / About Evaluate 3 Section 1 Pharma Industry Overview Top 15 Rx and OTC Sales 4 WW Rx and OTC Sales
More informationBusiness vs. Asset In Practice Potential Impacts of ASU , Clarifying the Definition of a Business
Business vs. Asset In Practice Potential Impacts of ASU 2017-1, Clarifying the Definition of a Business Jeff Ellis (Deloitte) & Tim Kocses (Bristol-Myers Squibb) Current GAAP What is a Business and Why
More informationBASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses. October 13, 2017
BASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses October 13, 2017 Cautionary note regarding forward-looking statements This presentation contains
More informationWESTFALIA AUTOMOTIVE ACQUISITION AUGUST 25, 2016
WESTFALIA AUTOMOTIVE ACQUISITION AUGUST 25, 2016 1 SAFE HARBOR STATEMENT FORWARD-LOOKING STATEMENTS This presentation may contain "forward-looking statements" as defined in the Private Securities Litigation
More informationThe Growth Strategy of Shionogi. September, 2011
The Growth Strategy of Shionogi September, 2011 Forward-Looking Statements This presentation contains forward-looking statements. These statements are based on expectations in light of the information
More informationIpsen Business and Strategy update
Ipsen Business and Strategy update ESN European Conference - London 10 December 2013 Pierre Kemula VP, Corporate Finance, Treasury and Financial Markets IPSEN pour nom de la société - 07/04/2011 / page
More information